+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Autologous CAR-T Cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma), Cell Target Antigen (Bcma, Cd19), Therapy Line, End User - Global Forecast 2025-2030- Product Image
Autologous CAR-T Cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma), Cell Target Antigen (Bcma, Cd19), Therapy Line, End User - Global Forecast 2025-2030- Product Image
New

Autologous CAR-T Cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non-Hodgkin Lymphoma), Cell Target Antigen (Bcma, Cd19), Therapy Line, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 199 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6130727
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The emergence of autologous CAR-T cell therapy represents a paradigm shift in oncology offering personalized treatment approaches for hematological malignancies. By harnessing a patient’s own immune cells and reprogramming them to target cancer antigens this innovative modality has transcended the limitations of traditional therapies and established new benchmarks in clinical efficacy. Early successes in treating refractory leukemias and lymphomas have underscored the transformative nature of this strategy fostering a wave of research investment and regulatory interest.

As the landscape matures stakeholders across biopharmaceutical companies contract development and manufacturing organizations and regulatory bodies continue to refine processes to support scalable production and broader patient access. Alongside technological advances in gene editing and cell manufacturing there is a concomitant evolution in health economic paradigms and reimbursement frameworks designed to reconcile high upfront costs with long-term clinical benefits. Through this convergence of scientific innovation and commercial imperatives autologous CAR-T cell therapy has emerged as a cornerstone of next-generation cancer treatment.

Revolutionary shifts in the autologous CAR-T therapy ecosystem reshaping treatment paradigms and stakeholder strategies across global healthcare landscapes

Revolutionary developments in vector design and manufacturing platforms have propelled autologous CAR-T therapy from laboratory experimentation to real-world application. Innovations in viral transduction and non-viral gene delivery techniques have significantly reduced production timelines while enhancing product consistency. Furthermore the integration of closed-system manufacturing solutions and modular clean-room operations has improved scalability and mitigated contamination risks.

In parallel regulatory agencies have introduced adaptive approval pathways and conditional authorizations to expedite patient access while maintaining rigorous safety standards. Collaborative alliances between academic centers and industry partners have enriched the clinical development ecosystem enabling smoother trial enrollment and data sharing. Moreover, the surging interest from venture capital and strategic investors has unlocked new funding streams to support both early-stage research and late-phase commercialization activities. Collectively these shifts underscore a rapidly evolving ecosystem where technological prowess contractual agility and regulatory alignment coalesce to redefine the future of cell therapy.

Anticipated United States tariffs scheduled for 2025 impacting autologous CAR-T manufacturing economics supply chain resilience and international collaboration

Anticipated changes to tariff policies in the United States slated for 2025 introduce a new dimension of complexity to the autologous CAR-T supply chain. Key raw materials and critical reagents sourced from international vendors may face elevated duties thereby inflating manufacturing costs and pressuring profit margins. Consequently organizations will need to conduct granular cost-benefit analyses and explore mitigation strategies such as reshoring certain production steps or negotiating long-term procurement contracts to maintain price competitiveness.

Beyond direct cost implications tariffs may also influence cross-border collaborations and clinical trial logistics. Institutions that rely on seamless import of reagents and equipment will need to reassess their partnerships and distribution networks to avoid delays in cell manufacturing workflows. Stakeholders are now evaluating alternative sourcing regions and strengthening local supplier relationships to reinforce resilience against potential trade disruptions. In this evolving environment proactive scenario planning and agile operational frameworks will be imperative to sustain uninterrupted access to life-saving therapies and preserve market momentum.

Comprehensive market segmentation insights shedding light on indication cell target antigen therapy line and healthcare end user dynamics in autologous CAR-T arena

A granular understanding of market segmentation unveils the distinct dynamics shaping autologous CAR-T adoption across various disease indications. Hematological malignancies such as acute lymphoblastic leukemia and chronic lymphocytic leukemia have demonstrated differentiated clinical outcomes prompting tailored trial designs and reimbursement strategies. In parallel multiple myeloma subpopulations characterized by newly diagnosed and relapsed refractory presentations demand bespoke product profiles that align with evolving standard-of-care regimens. Meanwhile diverse non-Hodgkin lymphoma cohorts including diffuse large B-cell lymphoma follicular lymphoma and mantle cell lymphoma exhibit variable antigen expression patterns necessitating specialized engineering approaches.

Delving deeper segmentation by cell target antigen highlights competitive and complementary trajectories between BCMA and CD19 directed therapies. Each antigen exhibits distinct efficacy safety and disease-specific adoption parameters influencing clinical positioning and portfolio prioritization. Furthermore therapy line stratification underscores the importance of first-line second-line and advanced salvage settings in shaping trial endpoints and payer negotiations. Finally end-user segmentation across ambulatory care centers hospitals and specialty clinics reveals operational considerations from point-of-care infusion capacities to post-administration monitoring infrastructure. This multidimensional framework forms the foundation for strategic decision-making and market entry optimization.

Key regional insights exploring unique drivers challenges and growth opportunities across Americas EMEA and Asia Pacific territories in autologous CAR-T sector

Regional markets present unique catalysts and challenges that influence the adoption trajectory of autologous CAR-T therapies. In the Americas regulatory bodies have led the way with precedent-setting approvals and value-based reimbursement initiatives, establishing a fertile environment for early commercial launches. The presence of world-class clinical research institutions and specialized manufacturing hubs further cements the region’s leadership role.

Conversely the Europe Middle East and Africa region exhibits a more heterogeneous landscape where divergent regulatory frameworks and reimbursement mechanisms require nuanced market access strategies. Pioneering health technology assessment models coexist with emerging markets that demand cost-containment solutions and tailored payment structures. Stakeholders are adopting collaborative models with payers and government bodies to align on outcome-based contracting and outcome registries.

In Asia Pacific, rapid expansion of healthcare infrastructure coupled with growing government investment in biotechnology underpins rising demand for innovative therapies. While regulatory harmonization remains a work in progress leading markets have begun introducing expedited approval pathways. At the same time rising middle class populations and expanding hospital networks provide a robust platform for scaling autologous CAR-T programs across the region.

Critical competitive landscape analysis highlighting leading biotech pharmaceutical and research institutions driving innovation in autologous CAR-T therapy market

The competitive landscape of autologous CAR-T therapy is defined by a mix of established pharmaceutical companies agile biotech innovators and leading academic spin-outs. Several industry frontrunners have successfully transitioned early-stage clinical programs into commercially approved products, leveraging deep pockets and extensive development expertise. Their strategic collaborations with contract development and manufacturing organizations have expedited capacity expansions and facilitated multi-regional supply chain networks.

At the same time a wave of emerging players is challenging conventional paradigms by advancing next-generation constructs including dual-antigen targeting and non-viral delivery systems. These newcomers often emphasize streamlined manufacturing processes and cost-effective scaling models to capture underserved patient populations. Additionally consortiums between global research institutions and biotech startups have cultivated vibrant ecosystems for knowledge exchange and co-development initiatives. Collectively, this constellation of participants continues to spur innovation competitive differentiation and evolving partnership models.

Strategic recommendations guiding industry leaders toward optimizing development regulatory approval and commercialization strategies for autologous CAR-T therapies

Industry leaders must prioritize integrated manufacturing strategies that balance centralized expertise with regional agility to mitigate trade risk and ensure reliable supply. Developing flexible production modalities that allow rapid scale-up or scale-down based on clinical demand will be essential to sustaining operational efficiency. Additionally engaging proactively with regulatory authorities to co-design adaptive licensing frameworks can shorten approval cycles and build trust in novel cell therapy modalities.

Moreover establishing value-based reimbursement agreements in collaboration with payers will align payment structures with long-term patient outcomes. Demonstrating real-world effectiveness through digital health platforms and patient registries can further reinforce the economic argument and support favorable coverage decisions. Finally cultivating strategic alliances with clinical sites contract developers and academic centers will accelerate patient enrollment enhance data sharing and foster iterative improvements in product design and delivery.

Rigorous research methodology detailing primary secondary data collection validation and analytical frameworks informing autologous CAR-T therapy insights

This report integrates a robust methodology combining qualitative and quantitative research approaches. Primary data collection included in-depth interviews with key opinion leaders clinicians and payers to capture nuanced perspectives on clinical performance and market access challenges. Secondary research involved systematic review of peer-reviewed publications regulatory filings and corporate disclosures to validate therapeutic mechanisms and competitive positioning.

Analytical frameworks such as SWOT analysis and value chain assessment were employed to distill critical drivers and barriers. Data triangulation techniques ensured the reliability of insights by cross-verifying findings from multiple sources. Throughout the study econometric modeling and scenario planning provided context for understanding potential impacts of shifting regulatory policies and tariff changes. This rigorous approach underpins the actionable intelligence presented in each section of the report.

Forward looking conclusions synthesizing key findings market implications and future research trajectories in the autologous CAR-T therapy landscape

In synthesizing the multifaceted developments across technology regulatory and commercial domains it becomes evident that autologous CAR-T cell therapy stands at an inflection point. Advances in manufacturing and gene delivery have begun to alleviate traditional bottlenecks, while adaptive regulatory frameworks lay the groundwork for broader patient access. Nonetheless external pressures such as evolving tariff regimes and regional reimbursement heterogeneity underscore the need for proactive risk management.

Looking ahead stakeholders will need to combine data-driven decision-making with flexible operational models to navigate an increasingly complex environment. As research continues to expand into novel antigen targets and combination regimens the ecosystem will demand deeper collaboration across biopharma contract manufacturing and healthcare providers. By aligning on shared objectives and leveraging emerging technologies the industry can accelerate the realization of personalized cell therapies for patients worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Indication
    • Leukemia
      • Acute Lymphoblastic Leukemia
      • Chronic Lymphocytic Leukemia
    • Multiple Myeloma
      • Newly Diagnosed
      • Relapsed Refractory
    • Non-Hodgkin Lymphoma
      • Diffuse Large B-Cell Lymphoma
      • Follicular Lymphoma
      • Mantle Cell Lymphoma
  • Cell Target Antigen
    • Bcma
    • Cd19
  • Therapy Line
    • First Line
    • Second Line
    • Third Line And Beyond
  • End User
    • Ambulatory Care Centers
    • Hospitals
    • Specialty Clinics
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Oxford BioMedica plc
  • Poseida Therapeutics, Inc.
  • Autolus Therapeutics plc
  • Takara Bio Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rising adoption of dual-targeting CAR-T therapies to overcome tumor antigen escape
5.2. Expansion of automated closed-system manufacturing platforms to scale autologous CAR-T production
5.3. Integration of real-world evidence to refine patient stratification and optimize CAR-T outcomes
5.4. Strategic partnerships between biotech companies and academic centers for next-gen autologous CAR-T research
5.5. Implementation of point-of-care manufacturing hubs to reduce vein-to-vein time and logistics bottlenecks in CAR-T therapy
5.6. Adoption of gene editing tools like CRISPR to enhance persistence and safety of autologous CAR-T cells
5.7. Evolution of reimbursement frameworks and value-based pricing models influencing autologous CAR-T access and adoption
5.8. Regulatory harmonization efforts by global health authorities to streamline autologous CAR-T therapy approvals
5.9. Advancements in CAR design such as armored CAR-T cells for improved efficacy against solid tumor indications
5.10. Emerging clinical data on long-term follow-up and durability of response in autologous CAR-T treated patients
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Autologous CAR-T Cell Therapy Market, by Indication
8.1. Introduction
8.2. Leukemia
8.2.1. Acute Lymphoblastic Leukemia
8.2.2. Chronic Lymphocytic Leukemia
8.3. Multiple Myeloma
8.3.1. Newly Diagnosed
8.3.2. Relapsed Refractory
8.4. Non-Hodgkin Lymphoma
8.4.1. Diffuse Large B-Cell Lymphoma
8.4.2. Follicular Lymphoma
8.4.3. Mantle Cell Lymphoma
9. Autologous CAR-T Cell Therapy Market, by Cell Target Antigen
9.1. Introduction
9.2. Bcma
9.3. Cd19
10. Autologous CAR-T Cell Therapy Market, by Therapy Line
10.1. Introduction
10.2. First Line
10.3. Second Line
10.4. Third Line And Beyond
11. Autologous CAR-T Cell Therapy Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Hospitals
11.4. Specialty Clinics
12. Americas Autologous CAR-T Cell Therapy Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Autologous CAR-T Cell Therapy Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Autologous CAR-T Cell Therapy Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Novartis AG
15.3.2. Gilead Sciences, Inc.
15.3.3. Bristol-Myers Squibb Company
15.3.4. Johnson & Johnson
15.3.5. Legend Biotech Corporation
15.3.6. Miltenyi Biotec GmbH
15.3.7. Oxford BioMedica plc
15.3.8. Poseida Therapeutics, Inc.
15.3.9. Autolus Therapeutics plc
15.3.10. Takara Bio Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. AUTOLOGOUS CAR-T CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2024 VS 2030 (%)
FIGURE 8. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AUTOLOGOUS CAR-T CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. AUTOLOGOUS CAR-T CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. AUTOLOGOUS CAR-T CELL THERAPY MARKET: RESEARCHAI
FIGURE 24. AUTOLOGOUS CAR-T CELL THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 25. AUTOLOGOUS CAR-T CELL THERAPY MARKET: RESEARCHCONTACTS
FIGURE 26. AUTOLOGOUS CAR-T CELL THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. AUTOLOGOUS CAR-T CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NEWLY DIAGNOSED, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NEWLY DIAGNOSED, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 87. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 91. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 94. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 95. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 96. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 97. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 98. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 99. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 100. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 101. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 102. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 103. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 104. CANADA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 105. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 106. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 107. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 108. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 109. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 110. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 111. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 112. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 113. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 114. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 115. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 116. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 117. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. MEXICO AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 129. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 130. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 177. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 180. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 181. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 182. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 183. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 184. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 185. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 186. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 187. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. GERMANY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 192. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 193. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 194. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 195. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 196. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 197. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 198. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 199. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 200. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 201. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 202. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 203. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. FRANCE AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 217. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. RUSSIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 220. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 221. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 222. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 223. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 224. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 225. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 226. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 227. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 228. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 229. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 230. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 231. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. ITALY AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 234. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 236. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 237. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 238. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 239. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 240. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 241. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 242. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 243. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 244. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 245. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. SPAIN AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 257. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 258. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 259. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. UNITED ARAB EMIRATES AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 271. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 272. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 273. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SAUDI ARABIA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 286. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. SOUTH AFRICA AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 290. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 291. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 292. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2030 (USD MILLION)
TABLE 293. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
TABLE 294. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2030 (USD MILLION)
TABLE 295. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
TABLE 296. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY NON-HODGKIN LYMPHOMA, 2025-2030 (USD MILLION)
TABLE 297. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2018-2024 (USD MILLION)
TABLE 298. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY CELL TARGET ANTIGEN, 2025-2030 (USD MILLION)
TABLE 299. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2018-2024 (USD MILLION)
TABLE 300. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY THERAPY LINE, 2025-2030 (USD MILLION)
TABLE 301. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 302. DENMARK AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS AUTOLOGOUS CAR-T CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
TABLE 306. NETHER

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Autologous CAR-T Cell Therapy market report include:
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Oxford BioMedica plc
  • Poseida Therapeutics, Inc.
  • Autolus Therapeutics plc
  • Takara Bio Inc.

Related Topics

Related Reports

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cell Therapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From
CAR T-cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma), Cell Source (Allogeneic, Autologous), Generation, Line Of Therapy, Target Antigen, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

CAR T-cell Therapy Market by Indication (Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma), Cell Source (Allogeneic, Autologous), Generation, Line Of Therapy, Target Antigen, End User - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 197 Pages
  • Global, United States Global, United States
From
CAR T-cell Therapy - Pipeline Insight, 2025 - Product Image

CAR T-cell Therapy - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2032 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2032

  • Report
  • 200 Pages
  • Global
From
Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Autologous CAR-T Cell Therapy Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.